Takeda Pharmaceutical Company Limited

4502.T

JPX

4217

JPY

+17.00(+0.40%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Takeda Pharmaceutical Company Limited fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

49.22

Price/Book

0.96

Debt/Equity

65.11%

Return on Equity

1.48%

Dividend Yield

4.65%

EBITDA

1.15T

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Statements Highlights

AnnualQuarterly

Period Ending	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025
Total Revenue	3,197,812,000,000	3,569,006,000,000	4,027,478,000,000	4,263,762,000,000	4,581,551,000,000
Gross Profit	2,203,504,000,000	2,462,160,000,000	2,783,406,000,000	2,832,257,000,000	2,358,101,000,000
Operating Income	509,269,000,000	460,844,000,000	490,505,000,000	214,075,000,000	523,108,000,000
Net Income	376,005,000,000	230,059,000,000	317,017,000,000	144,067,000,000	107,928,000,000
Total Assets	12,912,293,000,000	13,178,018,000,000	13,957,750,000,000	15,108,792,000,000	14,248,344,000,000
Total Current Liabilities	1,773,176,000,000	2,145,730,000,000	2,481,940,000,000	2,313,103,000,000	2,506,521,000,000
Total Equity	5,177,177,000,000	5,683,523,000,000	6,354,671,000,000	7,274,005,000,000	6,935,979,000,000
Free Cash Flow	774,463,000,000	937,068,000,000	343,467,000,000	235,614,000,000	761,698,000,000
Cash from Operations	1,010,931,000,000	1,123,105,000,000	977,156,000,000	716,344,000,000	962,493,000,000
Cash from Investing	393,530,000,000	-198,125,000,000	-607,102,000,000	-463,862,000,000	-385,355,000,000
Cash from Financing	-1,088,354,000,000	-1,070,265,000,000	-709,148,000,000	-354,416,000,000	-638,441,000,000
Net Change in Cash	328,608,000,000	-116,527,000,000	-316,165,000,000	-75,730,000,000	0